Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
XMT‑1660: A Phase 1b Trial of a B7‑H4–Targeting Antibody‑Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers
XMT-1660: A Phase 1b Trial of a B7-H4–targeting Antibody-Drug Conjugate (ADC) in Endometrial, Ovarian, and Breast Cancers
Anti-tumor Effect of XMT-1660, a B7-H4 Targeting Antibody Drug Conjugate, in an Unselected Panel of Patient Derived Xenograft Models of Breast Cancer
April, 2022
Site Specific Dolasynthen ADCs Demonstrate Consistent Exposure Across a Wide Range of Drug-To-Antibody Ratios
October, 2021
XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer
April, 2021
XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma
June, 2020
Mersana’s Innovative ADC Platforms – World ADC Summit 2019
October 2019
Dolasynthen: A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform
April 2019